產(chǎn)品屬性：
產(chǎn)品名稱 | Tocilizumab |
規(guī)格 | 1mg、5mg |
貨號 | EY-01Y10582 |
Cas No.: 375823-41-9
別名: N/A
化學(xué)名: N/A
分子式: N/A
分子量: N/A
溶解度: Soluble in DMSO
儲(chǔ)存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Tocilizumab (Anti-Human IL6R) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R) is approved for the treatment of rheumatoid arthritis in Europe and the United States[1].
Tocilizumab (Anti-Human IL6R) (1, 10, and 100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].Tocilizumab (Anti-Human IL6R) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].Tocilizumab (Anti-Human IL6R) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].Tocilizumab (Anti-Human IL6R) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3]. Cell Proliferation Assay[2] Cell Line: Human-derived HARA-B cells
Tocilizumab (Anti-Human IL6R) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].Tocilizumab (Anti-Human IL6R) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
[1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70. [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515-526. [3]. Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma
特別提醒公司產(chǎn)品僅供科研使用
